key: cord-0252203-t47uret2
authors: Knyazev, Sergey; Chhugani, Karishma; Sarwal, Varuni; Ayyala, Ram; Singh, Harman; Karthikeyan, Smruthi; Deshpande, Dhrithi; Comarova, Zoia; Lu, Angela; Porozov, Yuri; Wu, Aiping; Abedalthagafi, Malak S.; Nagaraj, Shivashankar H.; Smith, Adam L.; Skums, Pavel; Ladner, Jason; Tsan-Yuk Lam, Tommy; Wu, Nicholas C.; Zelikovsky, Alex; Knight, Rob; Crandall, Keith A.; Mangul, Serghei
title: Unlocking capacities of viral genomics for the COVID-19 pandemic response
date: 2021-04-28
journal: ArXiv
DOI: nan
sha: cc2b973073afbb2a88169a7895a30b06c5efb260
doc_id: 252203
cord_uid: t47uret2

More than any other infectious disease epidemic, the COVID-19 pandemic has been characterized by the generation of large volumes of viral genomic data at an incredible pace due to recent advances in high-throughput sequencing technologies, the rapid global spread of SARS-CoV-2, and its persistent threat to public health. However, distinguishing the most epidemiologically relevant information encoded in these vast amounts of data requires substantial effort across the research and public health communities. Studies of SARS-CoV-2 genomes have been critical in tracking the spread of variants and understanding its epidemic dynamics, and may prove crucial for controlling future epidemics and alleviating significant public health burdens. Together, genomic data and bioinformatics methods enable broad-scale investigations of the spread of SARS-CoV-2 at the local, national, and global scales and allow researchers the ability to efficiently track the emergence of novel variants, reconstruct epidemic dynamics, and provide important insights into drug and vaccine development and disease control. Here, we discuss the tremendous opportunities that genomics offers to unlock the effective use of SARS-CoV-2 genomic data for efficient public health surveillance and guiding timely responses to COVID-19.

More than any other infectious disease epidemic, the COVID-19 pandemic has been characterized by the generation of large volumes of viral genomic data at an incredible pace due to recent advances in high-throughput sequencing technologies, the rapid global spread of SARS-CoV-2, and its persistent threat to public health. However, distinguishing the most epidemiologically relevant information encoded in these vast amounts of data requires substantial effort across the research and public health communities. Studies of SARS-CoV-2 genomes have been critical in tracking the spread of variants and understanding its epidemic dynamics, and may prove crucial for controlling future epidemics and alleviating significant public health burdens. Together, genomic data and bioinformatics methods enable broad-scale investigations of the spread of SARS-CoV-2 at the local, national, and global scales and allow researchers the ability to efficiently track the emergence of novel variants, reconstruct epidemic dynamics, and provide important insights into drug and vaccine development and disease control. Here, we discuss the tremendous opportunities that genomics offers to unlock the effective use of SARS-CoV-2 genomic data for efficient public health surveillance and guiding timely responses to COVID-19.

COVID-19, a contagious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has reached an extraordinary scale not seen since the influenza pandemic of 1918-1919 1 . Within a month of its first reported case in China in December 2019, COVID-19 had spread to many regions in China 2 and had been detected in several neighboring countries, including Thailand, Korea, and Japan. As international flights continued to operate, SARS-CoV-2 then spread to Europe and North America in a short amount of time, and was soon declared a global pandemic 3, 4 . According to the World Health Organization (WHO), in the first 16 months of the pandemic (through April 8, 2021), more than 132.7 million people became infected worldwide, resulting in more than 2.8 million deaths 5 .

Over the past two decades, the biomedical community has become equipped with infrastructure for basic genomic techniques to support epidemic responses 6 , a capability that has enabled the rapid collection of SARS-CoV-2 genomic information which has allowed observation of SARS-CoV-2 genomic evolution online, rapid tracking of SARS-CoV-2 genetic groups, lineages, variants, variants of interest (VOI) and variants of concern (VOC) 7 . The precise and rapid tracking of SARS-CoV-2 genetic changes facilitates fast development of SARS-CoV-2 clinical tests and predicting the efficiency of the vaccines. As sequencing technologies and genomic analysis tools progress, genome sequencing is becoming more widely integrated into clinical and healthcare workflows. However, the utilization of genomic sequencing to its full potential for public health surveillance and outbreak response efforts has yet to be established and depends on the broad expansion of the best practices for preventing and limiting outbreaks that had been determined during the COVID-19 response 8 . Herein, we discuss the genomic capacities that can be used to address many of the public health issues associated with COVID-19 (Box 1).

Genomic analysis conducted on respiratory specimens isolated from the first COVID-19 patients hospitalized in December, 2019, in Wuhan, China, allowed for the prompt detection and characterization of a novel coronavirus, later named SARS-CoV-2, by January 2020 3, 4, 9, 10 . Initial sequence analyses revealed that SARS-CoV-2 shared 80% nucleotide identity with SARS-CoV 11, 12 , strongly indicating that SARS-CoV-2 was likely a respiratory pathogen that could spread from human to human and hence with clear epidemic potential. These initial analyses also revealed that SARS-CoV-2 shared high sequence similarity with related viruses found in bats and pangolins, suggesting a zoonotic origin 10, 11, [13] [14] [15] [16] [17] [18] [19] . Across its complete genome, SARS-CoV-2 is most closely related to the bat coronavirus RaTG13, with which it shares approximately 96% nucleotide sequence identity. However, different SARS-CoV-2 coding regions share greater similarity to those of other animal coronaviruses. For example, the spike (S) protein receptor-binding domain (RBD) exhibits higher sequence identity (97.4%) to that of the Guangdong pangolin virus, rather than to RaTG13 (89.3%), while SARS-CoV-2 long 1ab

(replicase) open reading frame (ORF) exhibits the highest sequence identity (98.8%) with the RmYN02 bat coronavirus 20 . In further support of zoonotic origin, another coronavirus detected in five bats (RacCS203) is genetically closely related to SARS-CoV-2 21 , and neutralizing antibodies for SARS-CoV-2 were found in wild pangolins and bats from Thailand 21 . Moreover, there is similarity between SARS-CoV-2 zoonosis and the zoonoses of the SARS-CoV and MERS-CoV coronaviruses, as data indicate that in all three cases, other intermediate animals were likely present in their transmission chains 22,23 . Together, these findings suggest a complex history of recombination events prior to the zoonotic transfer of SARS-CoV-2 to humans, although when and in which hosts these events took place remains unclear 13, 14, 19, 24 . Genomic knowledge acquired through viral sequencing and phylogenetic analysis greatly contributed to the rapid determination of the potential epidemiological characteristics and origins of SARS-CoV-2 25 .

As seen with other recent viral epidemics, viral genome sequencing has become an essential part of the COVID-19 public health response 26 . Early access to SARS-CoV-2 genome sequences allowed for the timely development and production of nucleic acid amplification testing (NAAT)-based diagnostics, expedited vaccine development, and accelerated opportunities for SARS-CoV-2 genomics-based real-time surveillance 27-32 . The first SARS-CoV-2 tests and vaccine candidates appeared within one and three months, respectively, after the identification of the first COVID-19 patient 32-34 . Together with access to modern sequencing technologies , the scale of the pandemic, based on numbers of cases and affected regions, has prompted the collection of SARS-CoV-2 viral genomic data at an unparalleled magnitude (on average 2,500 genomes per day). Consequently, the capacity to track virus spread and evolution in real time has been accelerated relative to that associated with prior outbreaks 35 . When the WHO initially declared a Public Health Emergency of International Concern (PHEIC) on January 30, 2020, 339 SARS-CoV-2 genomes had already been collected and characterized [2] [3] [4] 28 . By April 7, 2021, public repositories that host SARS-CoV-2 genomes contained over 1,000,000 genomes 36-38 (Table S1) .

Notably, by the end of the sixth month of the pandemic (May 2020), Global Initiative on Sharing All Influenza Data (GISAID) and the National Center for Biotechnology Information (NCBI) databases included 110,000 SARS-CoV-2 full-length genome sequences as compared to more than the 8,000 HIV full-length genome sequences collected by the Los Alamos sequence National Laboratory 39 over the past 40 years 40 (Figure 1a) . 86% of available SARS-CoV-2 raw sequencing data at NCBI is Illumina data, 13.7% is Oxford Nanopore, and 0.3% is Pacbio, IonTorrent and BGISEQ ( Figure S1 ). There is a correlation between the number of submitted sequences per capita and the GDP per capita for the majority of the countries in the world, moreover, high-income countries submitted about 100x more sequences per capita on average than did low-income countries (Figure 1b, S2) . However, it is remarkable that African nations with a low GDP per capita sequenced viral genomes on a level comparable to that of middle-and high-income countries 41 . Indeed, due to several previous programs that were aimed at controlling outbreaks of other viruses in Africa, the sequencing capacity of the African healthcare system improved, helping to increase its efficiency in the sequencing of SARS-CoV-2 genomes 41 (Figure 1c) . Countries with the highest ratios for numbers of SARS-CoV-2 genomes sequenced to numbers of COVID-19 cases and relatively low number of reported cases per capita were Taiwan, New Zealand, Australia, Iceland, and Denmark (Figure 1d ).

The unprecedented scale of SARS-CoV-2 genome sequencing offers unique opportunities for tracking SARS-CoV-2 evolution online and detecting the emergence and spread of new VOI and VOC [42] [43] [44] (Figure 2 ). Due to SARS-CoV-2 genome sequencing and consequent bioinformatics analysis it was shown that because of an intrinsic RNA proofreading mechanism, coronaviruses exhibit lower mutation rates than do many other RNA viruses, such as Ebola virus and HIV [45] [46] [47] [48] .

In addition, their evolutionary (i.e., nucleotide substitution) rate partly reflects the action of host-dependent RNA-editing enzymes (e.g., APOBEC) 49 . Coronaviruses undergo a mean rate of approximately 1.12 x 10 -3 nucleotide substitutions per site per year. This is comparable to the SARS-CoV-1 mutation rate from 0.8 x 10 -3 to 2.38 x 10 -3 , Ebolavirus's mutation rate of 1.3 x 10 -3 and is lower than seasonal influenza mutation rate of 6.7 x 10 -3 and HIV mutation rate of 4.4 x 10 -3 45-47,50-52 .

Another important aspect of SARS-CoV-2 evolution is that SARS-CoV-2, like many other RNA viruses, can live in the host as a swarm of closely related variants within individual hosts and has a tendency for recombinations 53 . Genomic studies have demonstrated the presence of such intra-host diversity inside hosts 54-60 , with one study having identified between 1 and 52 haplotype variants in each of 25 clinical patients 54 . Identifying the factors that shape these intra-host viral population structures can promote a better understanding of short-term viral evolution, in addition to providing insights into host adaptation and drug and vaccine design. However, from the advent of the pandemic through approximately September 2020, there was no statistical evidence that any of the numerous characterized SARS-CoV-2 mutations had resulted in a loss or gain of function [45] [46] [47] . For example, one study analyzed all 48,454 SARS-CoV-2 genomes available from GISAID from late July of 2020 that had been sequenced throughout the world and identified 12,706 mutations, 398 of which were recurrent, and none of which were associated with a significant change in transmissibility 69 . During the summer of 2020, the D614G mutation in the viral S protein sparked attention because this new variant globally superseded the original SARS-CoV-2 strain globally. Phylogenetic analyses and clinical evidence indicated that, although the D614G variant was associated with both increased viral load and infectivity 68, 70 , it was also more susceptible to neutralizing antisera and was not linked to any change in vaccine efficacy or increased pathogenicity 71 .

The first SARS-CoV-2 viral variant of concern (VOC) for public health, known as variant B.1.1.7, was first detected in the UK in September 2020. Genomic analysis revealed that this B.1.1.7 variant had first arisen in late Summer or early Fall 2020, and then quickly spread through many countries, including Australia, Denmark, Italy, Iceland, the Netherlands, and now the US 72-74 .

However, the full pathogenic potential of this variant was not recognized until December 2020 72 .

The B.1.1.7 variant strain harbors at least 12 mutations, including 2 in the S protein: N501Y, which increases the ability of SARS-CoV-2 binding to its cellular receptor, ACE2, and P618H, which adjoins the furin cleavage site in the S protein [75] [76] [77] . Both mutations have been associated with a 40-80% increase in the transmissibility of this variant as compared to previous SARS-CoV-2 strains 72 . More recently, the B.1.1.7 variant was found to be associated with greater disease severity and an increased risk of death as compared to other variants 78 . In addition, the variant carries a ∆69-70 deletion that results in detection failure by some SARS-CoV-2 molecular tests, which can limit the successful tracing of this VOC 79 . However, there is no evidence thus far that this variant reduces vaccine efficacy.

The second VOC was discovered in, UK, in September 2020, and was characterized by several mutations, including E484K in the RBD of the S protein. This mutation, which was later discovered to have arisen independently in other viral variants around the world 80 , is associated with reduced neutralizing activity of human convalescent and post-vaccination sera. Additional VOCs related to B.1.1.7 include B.1.351, which was first detected in South Africa in November 2020, 81 where it spread rapidly. Although the latest reports indicate that this variant has also spread to Zambia and the US, there is no evidence that this mutation impacts disease severity 82 .

This variant also harbors multiple mutations in the S protein, such as K417N, E484K, and N501Y.

The third VOC, P.1, was detected in four travelers who arrived in Japan from Brazil in January The impact of the K417T mutation is not known. More recently, another genetic variant B.1.427/B.1.429 was declared as VOC because of its prevalence in the outbreak that happened in California. This variant is harboring the L452R mutation in the S protein that is suspected to confer SARS-CoV-2 antibody resistance, although it is less severe than the E484K mutation, which is associated with greatly reduced viral susceptibility to antibody neutralization 86 . The full and actual list of all VOI and VOC can be found at the official CDC page 87 .

Some of these variants were first independently identified in immunodeficient individuals in different countries, suggesting that their emergence may be the result of convergent evolution followed by rapid spread. For example, the appearance of the ΔH69/ΔV70 deletion was documented in an immunosuppressed individual through deep viral genome sequencing at 23 time points during the course of infection (101 days) 64 . A weakened host immune response can permit the virus to replicate with little or no control, increasing the likelihood for mutations to occur. The independent evolution of a given mutation in different geographic locations suggests that this mutation may confer an adaptive advantage to the virus, such as immune evasion or increased transmissibility, which is corroborated by clinical studies. Given the likely public health importance of these VOCs and VUIs, global surveillance for these and other new variants is expanding, as information for all SARS-CoV-2 lineages is now collected and made available online for the rapid evaluation of their epidemiologic and vaccine impact and short-term evolution based on individual data points 7, 88 . In order to gain better control over emerging VOC and VOI, A European Commission Recommendation dated 19 January 2021 stated that "all EU Member States should reach a capacity of sequencing at least 5% -and preferably 10% -of positive test results. In most Member States, the sequencing capacity for identification of SARS-CoV-2 variants is below the recommendation set by the European Commission to sequence 5-10% of SARS-CoV-2 positive specimens'' (Figure 1d ).

Access to rich and diverse publicly available SARS-CoV-2 genomic data across various regions has allowed scientists and public health officials to efficiently track routes along which COVID-19 outbreaks have spread locally and internationally ( Figure S3 ). In this context, phylogenetic and genetic network analyses can provide important public health information regarding viral epidemic spread 89, 90 . Importantly, as viruses accumulate genomic mutations within different populations, knowledge regarding such evolution can reveal transmission chains and distinguish imported cases from instances of local transmission if a sufficient number of samples is analyzed, ultimately identifying high risk transmission routes which should be subject to enhance public health control [91] [92] [93] [94] . Genomic analysis has allowed the identification of (Table S2) Combining genomic methods with clinical and geospatial data can help characterize viral infectivity, virulence, and death rates of circulating viral strains more accurately because epidemics in different areas of the world may have distinct characteristics that depend on viral genotype, as well the demographics of the host population. Specifically, integration and analysis of phylogenetic and epidemiologic data can provide a more complete understanding of the pandemic transmission dynamics 105 . Available genomic data can also be utilized to examine and partly explain the relationship between genetic variation in strains of SARS-CoV-2 and disease severity 106 . Findings from these studies can also help characterize mutation patterns in various hotspots and identify correlates of infection and death rates in these countries 107 . Novel approaches can be developed to combine population genomics and genetics to leverage the identification of molecular markers with unusual pattern variations or relevant single nucleotide polymorphisms in people from different geographies 67, 68 . If SARS-CoV-2 infections continue at their current rate, population genomic research and pharmacogenomics approaches may be useful in the development of personalized therapeutics against this pathogen. Although disease severity can be partly attributed to host genomics, understanding these factors has been difficult due to contradictory evidence and limited host genomics studies conducted thus far to date 108 . 

Another genomics-based method for population-level pathogen surveillance assesses the presence of trace viral genomic material in wastewater, with this approach having been successfully employed to track antibiotic use 109 Alternatively, a potentially promising approach is the application of metagenomics on a global scale to detect, collect, and store samples in preparation for future pandemics 117, 118 .

Metagenomics methods, which can sequence all available genomic material in a sample, allow the characterization of an entire viral population and the detection of prevalent SARS-CoV-2 variants in a given geographical space 119, 120 . Wastewater surveillance studies of SARS-CoV-2 RNA concentration across various regions in the world have taken place between January 2020 and November 2020. (Figure 1e, Table S3 ).

Temporal changes in SARS-CoV-2 RNA concentration in wastewater were assessed in Valencia, Spain from February till April 2020, Paris, France from March till April 2020, and in many other regions (see Table S3 ), they have been consistent with the number of clinically diagnosed cases in a given community 121, 122 . This relationship demonstrates the use of wastewater studies as a relatively inexpensive and straightforward method for investigating national outbreak dynamics, especially in areas where case diagnosis is complicated. In contrast, clinical diagnostic testing traditionally used to assess the number of cases in a community typically underestimates actual infection rates 123 , as this approach primarily focuses on symptomatic individuals because the asymptomatic cases are less likely to be captured. However, combining clinical diagnostics with wastewater-based surveillance can potentially provide a more comprehensive community-level profile of both symptomatic and asymptomatic cases, enabling identification of hospital capacity needs 114, [124] [125] [126] [127] [128] [129] [130] . Additionally, an important advantage of wastewater monitoring is the ability to detect early-stage outbreaks before they become widespread 111, 115, 131, 132 . In contrast to NAAT-based methods such as real time reverse transcription polymerase chain reaction (RT-PCR)-based analysis of SARS-CoV-2, metagenomic sequencing allows for characterization of the prevalent SARS-CoV-2 genomic variants in a defined local region and reveal geospatial SARS-CoV-2 genotype distribution 120, 133 . Using wastewater samples can identify circulating lineages in the community and accompany analysis of genomic epidemiology, for example, such analysis has already helped to detect B.1.1.7 strains in the US and Switzerland 134 .

Despite the numerous advantages of wastewater-based virus surveillance, many potential improvements would result in more reliable and extended applications in public health decision-making. Currently, wastewater-based methods require calibration and validation because they only provide a raw measure of the number of cases in a population 115 .

Additionally, wastewater-based monitoring lacks the granularity of clinical diagnostic testing and cannot discern a particular area of an outbreak when the wastewater treatment plant serves a large population. Sampling at a higher spatial resolution within the sewer system or even at a building-level scale could potentially provide early indications of viral outbreaks and help monitor their progression 135 . This effort could also include areas with large numbers of septic tank systems that are not feeding municipal wastewater systems.

Viral genomics can also aid in vaccine development and investigations of how viral evolution impacts clinical outcomes and treatment 136 . While the majority of known SARS-CoV-2 mutations have no effect on viral replication and transmission 137 , some substitutions have been linked to phenotypic changes that could influence outbreak dynamics. For example, patients in Singapore infected with ∆382 SARS-CoV-2 variants, which have a 382-nucleotide deletion in ORF8, exhibited milder symptoms compared to patients with viruses that lacked this deletion 138 . However, the ∆382 SARS-CoV-2 variant is very rare globally and appears to have died out in Singapore. More alarmingly, the highly prevalent D614G mutation may increase transmissibility and infectivity in natural populations, giving variants harboring this mutation a marked selective advantage, although the best evidence to date comes from laboratory and simulation studies only 68, 95, 139 . Lastly, the viral variants B.1.1.7, B.1.351, and P.1, which were detected in late 2020, showed significantly increased transmissibility, heightening concern from a public health perspective 82, 140, 141 . For vaccine development, understanding the degree to which different regions of the viral genome are prone to mutation is important, as it is necessary to understand whether rising immunity in humans will result in antigenic drift and consequent vaccine escape. These evolutionary effects are commonly seen, for example, in human influenza viruses and endemic coronaviruses. Analyses of the current genomic variability of SARS-CoV-2 suggest that prospective COVID-19 vaccines should be cross-protective for the majority of currently known viral variants 73,108,142 , although some minor variants (< 1% natural occurrence frequency) have been shown to alter the antigenicity of SARS-CoV-2 143 . For vaccine development, determining the structures of SARS-CoV-2 antigens and their mutants is also crucial for the maximization of vaccine efficacy 144 . The online COVID-3D resource allows for the exploration of the structural distribution of genetic variation in SARS-CoV-2 145 .

The antigenic drift may also affect the effectiveness of NAAT-testing because when mutations happen in primer regions, the effectiveness of tests drops due to loss of affinity. Therefore control over appearing mutations should be taken into account for updating NAAT tests as well.

The first lab-confirmed case of COVID-19 re-infection case was detected in Hong Kong using a genomic analysis approach 146 , after which additional re-infection cases were detected in Belgium, Ecuador, and the US [147] [148] [149] . Phylogenetic analyses of longitudinal SARS-CoV-2 genomic sequences for all these patients distinguished between patient re-infection and persistent viral shedding from the initial infection. The findings in all four cases suggest that SARS-CoV-2 may persist in the global human population, despite herd immunity due to natural infection, which can complicate vaccine development and efficacy 146 . However, current data suggests that SARS-CoV-2 re-infection is rare, and it has been proposed that immunity against reinfection can last for at least several months after the primary infection 150 .

Clinical manifestations of SARS-CoV-2 infection vary greatly, ranging from a lack of symptoms to irreversible pulmonary damage [151] [152] [153] . Adaptive immune responses, such as early CD8+ and CD4+

T cell responses, have been associated with positive patient outcomes 154 . Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients has also revealed differences in immune response characteristics between patients with a mild or severe disease 

Many SARS-CoV-2 genomic studies to date have been conducted in the absence of substantial clinical data collection and/or integration with viral sequence data. Conversely, numerous studies have critically evaluated extensive clinical data alone, without assessing corresponding genomic data 156 . Even investigations yielding large genomic (e.g., GISAID 28,36 ) and clinical datasets 157 have not performed integrated analyses of both data types. This substantial limitation of current practices results from distinctions between the fields of bioinformatics (genomic data analyses) and medical informatics (clinical data analyses). The COVID-19 pandemic promises to unite researchers from both of these fields to integrate these seemingly disparate data sources, especially in prospective studies 158 . Finding significant associations between genomic and clinical features of the virus will ultimately support more targeted interventions by public health officials.

The unprecedented density and volume of available SARS-CoV-2 genomic and clinical data enabled the prompt and effective characterization of both SARS-CoV-2 genomes and COVID-19 epidemiology compared to those of previous outbreaks. The numerous successful efforts across various parts of the globe utilizing genomic data for addressing the COVID-19 outbreak created a solid foundation for the standardization of using SARS-CoV-2 genomic data. High-income countries sequenced more SARS-CoV-2 sequences per population than the countries with low, middle-low and middle income. However, the countries of Africa with low and middle-low income demonstrated remarkably better preparedness to collect SARS-CoV-2 genomes than low and middle-low income countries from other continents (Figure 1b) . This preparedness can be At the same time, the unprecedented volume of SARS-CoV-2 genome sequencing that reached one million viral genomes sequences challenged the current practices of viral data storage, processing, and bioinformatics analysis [159] [160] [161] . While the importance of genome-based viral surveillance systems was widely recognized, the principle of such systems were conceptualized, and there were technological burdens of creating them, as such systems were still in the early stages of development before the pandemic started. However, the unprecedented mobilization of financial, scientific, and development resources during the course of COVID-19 allowed for fast development, deployment, and scaling of numerous global surveillance systems which provide resources for outbreak response using SARS-CoV-2 genome analysis ( Table 1) .

When rigorously studied, benchmarked, and standardized, viral genomic surveillance systems enable reliable and timely detection of the presence of circulating and emerging pathogens similar to SARS-CoV-2, providing us a robust shield from current and newly emerging outbreaks 162 . With sufficient sampling, genomic analysis will enable sentinel surveillance efforts capable of effectively locating the geographic source of outbreaks, elucidating transmission chains, and ultimately limiting the spread of the pathogens globally 99, 141, [163] [164] [165] [166] [167] .

Genomic analysis conducted on respiratory specimens isolated from the first COVID-19 patients hospitalized in December, 2019, in Wuhan, China, allowed for the prompt detection and characterization of a novel coronavirus, later named SARS-CoV-2, by January 2020 3, 4, 9, 10 .

Initial sequence analyses revealed that SARS-CoV-2 shared 80% nucleotide identity with SARS-CoV 11,12 , strongly indicating that SARS-CoV-2 was likely a respiratory pathogen that could spread from human to human and hence with clear epidemic potential. These initial analyses also revealed that SARS-CoV-2 shared high sequence similarity with related viruses found in bats and pangolins, suggesting a zoonotic origin 10, 11, [13] [14] [15] [16] [17] [18] [19] . Across its complete genome, SARS-CoV-2 is most closely related to the bat coronavirus RaTG13, with which it shares approximately 96% nucleotide sequence identity. However, different SARS-CoV-2 coding regions share greater similarity to those of other animal coronaviruses.

SARS-CoV-2 genome sequences allowed for the timely development and production of nucleic acid amplification testing (NAAT)-based diagnostics, expedited vaccine development, and accelerated opportunities for SARS-CoV-2 genomics-based, real-time surveillance 27-32 . By April 7, 2021, public repositories that host SARS-CoV-2 genomes contained over 1,000,000 genomes 36-38 (Table S1) . Notably, by the end of the sixth month of the pandemic (May 2020), Global Initiative on Sharing All Influenza Data (GISAID) and the National Center for Biotechnology Information (NCBI) databases included 110,000 SARS-CoV-2 full-length genome sequences as compared to more than the 8,000 HIV full-length genome sequences collected by the Los Alamos sequence National Laboratory 39 over the past 40 years 40 (Figure 1a) . 156 . This substantial limitation of current practices results from distinctions between the fields of bioinformatics (genomic data analyses) and medical informatics (clinical data analyses). The COVID-19 pandemic promises to unite researchers from both of these fields to integrate these seemingly disparate data sources, especially in prospective studies 158 . 

The Coronavirus and the Great Influenza Pandemic: Lessons from the 'Spanish Flu' for the Coronavirus's

Genomic Epidemiology of SARS-CoV-2 in Guangdong Province

A novel coronavirus outbreak of global health concern

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

COVID-19) -World Health Organization

Tracking virus outbreaks in the twenty-first century

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

The Rockefeller Foundation Releases New Action Plan to Accelerate Development of a National System for Gathering and Sharing Information on SARS-CoV-2 Genomic Variants and Other Pathogens

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

A pneumonia outbreak associated with a new coronavirus of probable bat origin

On the origin and continuing evolution of SARS-CoV-2

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

The proximal origin of SARS-CoV-2

Emergence of SARS-CoV-2 through recombination and strong purifying selection

Emerging Pandemic Diseases: How We Got to COVID-19

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

A Novel Coronavirus from Patients with Pneumonia in China

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible

Genomic-informed pathogen surveillance in Africa: opportunities and challenges

Mutations, Recombination and Insertion in the Evolution of

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

GESS: a database of global evaluation of SARS-CoV-2/hCoV-19 sequences

Variant analysis of SARS-CoV-2 genomes

Moderate mutation rate in the SARS coronavirus genome and its implications

The evolution of Ebola virus: Insights from the 2013-2016 epidemic

Mechanisms of viral mutation

Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2

Influenza Major Hospital Outbreaks in South

Characterization of SARS-CoV-2 viral diversity within and across hosts

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

SARS-CoV-2 evolution during treatment of chronic infection

The phylogenomics of evolving virus virulence

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

A Genomic Perspective on the Origin and Emergence of SARS-CoV-2

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2

Emergence of a Highly Fit SARS-CoV-2 Variant

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data

Covid-19: What have we learnt about the new variant in the UK?

First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August

The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells. Cold Spring Harbor Laboratory

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

NERVTAG note on B. 1.1. 7 severity. New & Emerging Threats Advisory Group

Screening of the H69 and V70 deletions in the SARS-CoV-2 spike protein with a RT-PCR diagnosis assay reveals low prevalence in Lyon

Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01 (PDF)

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Detection of B.1.351 SARS-CoV-2 Variant Strain -Zambia

Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK

Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

Massive Google-funded COVID database will track variants and immunity

Phylogenetic Trees and Networks Can Serve as Powerful and Complementary Approaches for Analysis of Genomic Data

Insights from SARS-CoV-2 sequences

Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States

Introductions and early spread of SARS-CoV-2 in France

Full genome viral sequences inform patterns of SARS-CoV-2 spread into and within Israel. medRxiv

Genomic Diversity of SARS-CoV-2 During Early Introduction into the United States National Capital Region. medRxiv

High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States

The origin and early spread of SARS-CoV-2 in Europe

The emergence of SARS-CoV-2 in Europe and North America

An Early Pandemic Analysis of SARS-CoV-2 Population Structure and Dynamics in Arizona

Introductions and early spread of SARS-CoV-2 in the New York City area

Routes for COVID-19 importation in Brazil

Genetic Diversity and Genomic Epidemiology of SARS-COV-2 in Morocco

Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling

Fast-spreading U.K. virus variant raises alarms

Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

Besides population age structure, health and other demographic factors can contribute to understanding the COVID-19 burden

Genetic variation in SARS-CoV-2 may explain variable severity of COVID-19

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Low genetic diversity may be an Achilles heel of SARS-CoV-2

Emerging investigators series: sewer surveillance for monitoring antibiotic use and prevalence of antibiotic resistance: urban sewer epidemiology

A novel approach for monitoring tobacco use in local communities by wastewater analysis

Future perspectives of wastewater-based epidemiology: Monitoring infectious disease spread and resistance to the community level

Detection of pathogenic viruses in sewage provided early warnings of hepatitis A virus and norovirus outbreaks

The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients

Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics

Wastewater and public health: the potential of wastewater surveillance for monitoring COVID-19

Viromic Analysis of Wastewater Input to a River Catchment Reveals a Diverse Assemblage of RNA Viruses

Coronavirus discovery by metagenomic sequencing: a tool for pandemic preparedness

A new twenty-first century science for effective epidemic response

Setting a baseline for global urban virome surveillance in sewage

Genome sequencing of sewage detects regionally prevalent SARS-CoV-2 variants

Metropolitan Wastewater Analysis for COVID-19 Epidemiological Surveillance

Evaluation of lockdown impact on SARS-CoV-2 dynamics through viral genome quantification in Paris wastewaters

SARS-CoV-2 Titers in Wastewater Are Higher than Expected from Clinically Confirmed Cases

Correlation of SARS-CoV-2 RNA in wastewater with COVID-19 disease burden in sewersheds

Presence of SARS-Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the Early Stage of the Epidemic in The Netherlands

First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: A proof of concept for the wastewater surveillance of COVID-19 in the community

COVID-19 surveillance in Southeastern Virginia using wastewater-based epidemiology

Presence of SARS-Coronavirus-2 in sewage

SARS-CoV-2 titers in wastewater foreshadow dynamics and clinical presentation of new COVID-19 cases

High throughput wastewater SARS-CoV-2 detection enables forecasting of community infection dynamics in San Diego county

Tracking COVID-19 with wastewater

Watcher in the wastewater

Monitoring SARS-CoV-2 circulation and diversity through community wastewater sequencing. Public and Global Health

Detection of SARS-CoV-2 variants in Switzerland by genomic analysis of wastewater samples

Rethinking wastewater risks and monitoring in light of the COVID-19 pandemic

Assessing the human immune response to SARS-CoV-2 variants

Viral and host factors related to the clinical outcome of COVID-19

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

Public health actions to control new SARS-CoV-2 variants

Surveillance of SARS-CoV-2 in Zimbabwe shows dominance of variants of concern

A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Exploring the structural distribution of genetic variation in SARS-CoV-2 with the COVID-3D online resource

COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing

Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain

COVID-19 re-infection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America

What reinfections mean for COVID-19

Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting

The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis

Organ-specific manifestations of COVID-19 infection

T cell-mediated immune response to respiratory coronaviruses

Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease

Factors associated with COVID-19-related death using OpenSAFELY

The National COVID Cohort Collaborative (N3C): Rationale, Design, Infrastructure, and Deployment

Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study

Scientists call for fully open sharing of coronavirus genome data

Want to track pandemic variants faster? Fix the bioinformatics bottleneck

One million coronavirus sequences: popular genome site hits mega milestone

Status of environmental surveillance for SARS-CoV-2 virus

How countries are using genomics to help avoid a second coronavirus wave

Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California

Using genomics to improve preparedness and response of future epidemics or pandemics in Africa

Lessons from New Zealand's COVID-19 outbreak response

Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands

Tracking the COVID-19 pandemic in Australia using genomics

Spread of SARS-CoV-2 in the Icelandic Population

Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand

Worldwide tracing of mutations and the evolutionary dynamics of SARS-CoV-2

SARS-CoV-2 Genome Analysis of Japanese Travelers in Nile River Cruise

Phylogenetic network analysis of SARS-CoV-2 genomes

Evolution and epidemic spread of SARS-CoV-2 in Brazil

A doubt of multiple introduction of SARS-CoV-2 in Italy: A preliminary overview

SARS-CoV-2 lineage B.6 is the major contributor to transmission in Malaysia

Cryptic transmission of SARS-CoV-2 in Washington state

Genomic epidemiology of the Los Angeles

Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area

Phylogenetic analysis of SARS-CoV-2 in the Boston area highlights the role of recurrent importation and superspreading events

Large scale sequencing of SARS-CoV-2 genomes from one region allows detailed epidemiology and enables local outbreak management

Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State

Genomic epidemiology reveals multiple introductions and spread of SARS-CoV-2 in the Indian state of Karnataka

Genomic epidemiology of the early stages of SARS-CoV-2 outbreak in Russia

Genomic epidemiology reveals multiple introductions of SARS-CoV-2 from mainland Europe into Scotland

Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2

Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity

Genomic analysis of SARS-CoV-2 reveals local viral evolution in Ghana

Phylogenetic supertree reveals detailed evolution of SARS-CoV-2

Phylogenetic analysis of SARS-CoV-2 in the first few months since its emergence

Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy

Phylogenetic analysis of the first four SARS-CoV-2 cases in Chile

SARS-CoV-2 Phylogenetic Analysis

Phylogenetic analysis of SARS-CoV-2 genomes in Turkey

Phylogenetic and phylodynamic analyses of SARS-CoV-2

Detection of SARS-CoV-2 in raw and treated wastewater in Germany -Suitability for COVID-19 surveillance and potential transmission risks

First detection of SARS-CoV-2 in untreated wastewaters in Italy

First Data-Set on SARS-CoV-2 Detection for Istanbul Wastewaters in Turkey

Regressing SARS-CoV-2 sewage measurements onto COVID-19 burden in the population: a proof-of-concept for quantitative environmental surveillance

Potential spreading risks and disinfection challenges of medical wastewater by the presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral RNA in septic tanks of Fangcang Hospital

SARS-CoV-2 in human sewage in Santa Catalina, Brazil

First environmental surveillance for the presence of SARS-CoV-2 RNA in wastewater and river water in Japan

First proof of the capability of wastewater surveillance for COVID-19 in India through detection of genetic material of SARS-CoV-2

Temporal Detection and Phylogenetic Assessment of SARS-CoV-2 in Municipal Wastewater

Preliminary Study of Sars-Cov-2 Occurrence in Wastewater in the Czech Republic

SARS-CoV-2 in wastewater settled solids is associated with COVID-19 cases in a large urban sewershed

Long-term monitoring of SARS-CoV-2 in wastewater of the Frankfurt metropolitan area in Southern Germany

Quantitative analysis of SARS-CoV-2 RNA from wastewater solids in communities with low COVID-19 incidence and prevalence

SARS-CoV-2 detection in Istanbul wastewater treatment plant sludges

SARS-CoV-2 in river water: Implications in low sanitation countries

Detection of SARS-CoV-2 RNA in commercial passenger aircraft and cruise ship wastewater: a surveillance tool for assessing the presence of COVID-19 infected travellers

SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area

Presence and vitality of SARS-CoV-2 virus in wastewaters and rivers

SARS-CoV-2 has been circulating in northern Italy since

Post-lockdown detection of SARS-CoV-2 RNA in the wastewater of

Sewage analysis as a tool for the COVID-19 pandemic response and management: the urgent need for optimised protocols for SARS-CoV-2 detection and quantification

Quantification of SARS-CoV-2 and cross-assembly phage (crAssphage) from wastewater to monitor coronavirus transmission within communities

US) Septemb er 30

We thank William M. Switzer and Ellsworth M. Campbell from the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, 30333 GA, USA for useful discussions and suggestions. We also thank numerous anonymous reviewers who helped improve our manuscript by their valuable comments on the manuscript.